Profile Response Detail

Molecular Profile TP53 mutant
Therapy Bevacizumab
Indication/Tumor Type colorectal cancer
Response Type sensitive
Create By csp
Update By smockus

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
TP53 mutant colorectal cancer sensitive Bevacizumab Phase III Actionable In a Phase III trial, Avastin (bevacizumab), in combination with chemotherapy, provided a significant survival benefit in patients with colorectal cancers regardless of mutational status in KRAS, BRAF, and TP53 (PMID: 17145525). 17145525
PubMed Id Reference Title Details
(17145525) Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer. Full reference...